These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Continuous and intermittent infusion of coagulation factor concentrates in patients undergoing surgery: a single centre Australian experience. Campbell PJ; Rickard KA Aust N Z J Med; 1998 Aug; 28(4):440-5. PubMed ID: 9777111 [TBL] [Abstract][Full Text] [Related]
6. Review of pumps for continuous infusion of coagulation factor concentrates: what are the options? Martinowitz U; Schulman S Blood Coagul Fibrinolysis; 1996 Mar; 7 Suppl 1():S27-33. PubMed ID: 8735794 [TBL] [Abstract][Full Text] [Related]
7. Continuous infusion of recombinant factor VIIa in patients with haemophilia and inhibitors. Experience in The Netherlands and Belgium. Mauser-Bunschoten EP; de Goede-Bolder A; Wielenga JJ; Levi M; Peerlinck K Neth J Med; 1998 Dec; 53(6):249-55. PubMed ID: 9883002 [TBL] [Abstract][Full Text] [Related]
8. Continuous infusion of coagulation factor concentrates during intensive treatment. Holme PA; Tjønnfjord GE; Batorova A Haemophilia; 2018 Jan; 24(1):24-32. PubMed ID: 28873263 [TBL] [Abstract][Full Text] [Related]
9. Design and assessment of clinical trials on continuous infusion. Schulman S; Martinowitz U Blood Coagul Fibrinolysis; 1996 Mar; 7 Suppl 1():S7-9. PubMed ID: 8735790 [TBL] [Abstract][Full Text] [Related]
10. Factors affecting choice of hemostatic agent for the hemophilia patient with an inhibitor antibody. Monahan PE; Aledort LM; Am J Hematol; 2004 Dec; 77(4):346-50. PubMed ID: 15558804 [TBL] [Abstract][Full Text] [Related]
11. Needles and needleless devices for infusion of anti-haemophilic factor concentrate: impact on protein structure and function. Prabhu S; Kazarian T; Hakobyan N; Jabbar A; Dunham T; Valentino LA Haemophilia; 2006 Jan; 12(1):58-61. PubMed ID: 16409176 [TBL] [Abstract][Full Text] [Related]
12. Prophylactic infusion regimens in the management of hemophilia. Ljung RC Thromb Haemost; 1999 Aug; 82(2):525-30. PubMed ID: 10605746 [TBL] [Abstract][Full Text] [Related]
13. Dose and outcome of care in haemophilia--how do we define cost-effectiveness? Fischer K; Van den Berg HM; Thomas R; Kumar S; Poonnoose P; Viswabandya A; Mathews V; Kavitha ML; Bhattacharji S; Srivastava A Haemophilia; 2004 Oct; 10 Suppl 4():216-20. PubMed ID: 15479401 [TBL] [Abstract][Full Text] [Related]
18. Prophylaxis and continuous infusion for hemophilia: can we afford it? Aledort LM; Bohn RL Blood Coagul Fibrinolysis; 1996 Mar; 7 Suppl 1():S35-7. PubMed ID: 8735795 [TBL] [Abstract][Full Text] [Related]
19. The safety of pharmacologic options for the treatment of persons with hemophilia. Franchini M; Mannucci PM Expert Opin Drug Saf; 2016 Oct; 15(10):1391-400. PubMed ID: 27367551 [TBL] [Abstract][Full Text] [Related]
20. [Continuous infusion of recombinant activated factor VII during and after elbow arthroplasty in a hemophilia A patient with inhibitors]. Nakamura M; Terashima K; Takashima Y; Amano K; Horikoshi Y; Mimaya J Rinsho Ketsueki; 2002 Mar; 43(3):183-8. PubMed ID: 11979750 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]